Abstract
The transcription factor NF-κB has attracted widespread interest based on its unusual regulation, the variety of stimuli that activate it, the diverse genes and biological responses that it controls, the striking evolutionary conservation of structure and function among family members, and its apparent involvement in a variety of human diseases. Recently NF-κB has been shown to be the target of new drug discovery. Here, we discuss the so-called NF-κB inhibitors and consider the development of new therapeutic agents.
